International Edition
Latest News
Health

Phase I/II Trial: KRAS Inhibitor Combo Erases Tumors on CT in 8.2% of Metastatic Pancreatic Cáncer Patients

In a phase I/II trial, 8.2 percent of patients with metastatic pancreatic cancer saw tumors vanish from CT scans after receiving an experimental KRAS inhibitor with chemotherapy. The combination of daraxonrasib, gemcitabine and nab-paclitaxel halted tumor growth in…

Phase I/II Trial: KRAS Inhibitor Combo Erases Tumors on CT in 8.2% of Metastatic Pancreatic Cáncer Patients

In a phase I/II trial, 8.2 percent of patients with metastatic pancreatic cancer saw tumors vanish from CT scans after receiving an experimental KRAS inhibitor with chemotherapy.

The combination of daraxonrasib, gemcitabine and nab-paclitaxel halted tumor growth in 90.2 percent of the 61 participants and shrank or eliminated lesions in 60.7 percent, researchers reported at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Barcelona. Median follow-up reached 18.3 months, according to trial data presented at the EORTC-NCI-AACR symposium; Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, said, “This is the closest thing to a cure I have seen in my career,” and told The Guardian, “Imagine that in an average of 18 months their disease just disappears on the scan… that is as close to a complete remission as you can get… it’s incredible.”

The trial, RMC-GI-102, enrolled treatment-naïve patients between 2023 and September 28, 2026. Participants took 200 milligrams of daraxonrasib daily by mouth alongside standard intravenous chemotherapy on days 1 and 15 of each cycle. Median progression-free survival was 12.8 months, and 76.6 percent of patients were alive at one year, eldebate.com reported. Historical one-year survival with chemotherapy alone ranges from 40 to 45 percent, infobae.com noted.

In the United Kingdom, pancreatic cancer registers about 11,500 new diagnoses each year and causes around 10,200 deaths annually, according to Cancer Research UK data. In the United States, the disease accounts for 3 percent of all cancers and 8 percent of cancer deaths, with approximately 53,000 deaths per year. The trial results were presented on 21 November 2026 at 07:16 a.m. EST.

Targeting the ‘undruggable’ KRAS mutation

More than 90 percent of pancreatic cancers carry mutations in the RAS gene family — most often KRAS — which lock growth signals in the “on” position. For decades the protein was considered undruggable because its smooth surface lacked obvious pockets for small molecules. Daraxonrasib binds the active RAS(ON) state and blocks downstream signaling, eldebate.com reported. During decades, these mutations were considered “untreatable” by the scientific community.

Dr Sam Godfrey, of CRUK, told the BBC: “What this new drug has achieved is finding a way to treat the untreatable. At last we are seeing progress in pancreatic cancer, something that has been pending for a very long time.”

The same mutations appear in subsets of lung, colorectal and biliary-tract cancers, raising the possibility that the approach could extend beyond pancreatic disease, labrujula24.com noted.

Phase I/II Trial: KRAS Inhibitor Combo Erases Tumors on CT in 8.2% of Metastatic Pancreatic Cáncer Patients
Photo: eldebate.com

Daraxonrasib causes rash diarrhea fatigue but few quit

The most common side effects tied to daraxonrasib were rash, diarrhea and fatigue. Chemotherapy-related cytopenias also occurred. Only 5 percent of patients discontinued the experimental drug because of adverse events, and researchers said toxicities were manageable with standard supportive care, eldebate.com reported.

Phase III trial underway to confirm benefit

The single-arm design prevents a direct comparison with chemotherapy alone. A global phase III study, RASolute-303, is now randomizing patients to daraxonrasib plus gemcitabine and nab-paclitaxel versus standard chemotherapy to determine whether the experimental regimen improves overall survival, eldebate.com reported, according to Eldebate. The phase III trial compares daraxonrasib, alone or combined with gemcitabine and nab-paclitaxel, against standard chemotherapy.

Park, who completed a medical oncology fellowship at the University of Miami and Jackson Memorial Hospital, holds board certifications in internal medicine and medical oncology. He directs the NIH-funded Pancreas SPORE (RP2, 2022–2027) and co-leads the Break Through Cancer Conquering KRAS Team Lab, both focused on KRAS-driven pancreatic tumors. He was named a Rising Star by the National Pancreas Foundation in 2021 and received the ASCO Conquer Cancer Foundation Merit Award in 2018.

Phase I/II Trial: KRAS Inhibitor Combo Erases Tumors on CT in 8.2% of Metastatic Pancreatic Cáncer Patients
Photo: infobae.com

Complete responses do not equal cure

Investigators emphasized that radiographic disappearance of tumors does not confirm eradication of all cancer cells. Disease could recur, and the duration of responses remains unknown. Longer follow-up and larger studies are needed to establish whether the deep responses translate into durable survival gains, noticiasdelacalle.com.ar reported.

Michelle Mitchell, chief executive of Cancer Research UK, called the data “the biggest breakthrough we have seen in decades for pancreatic cancer patients,” while cautioning that further trials are essential, labrujula24.com reported. Wungki Park said, “We are beginning to see not only a higher percentage of tumor response rates, but also deeper responses and almost double the duration of disease control, which could eventually translate into longer survival.”

About the author: Health Desk

Health Desk at Archynewsy.